Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeoVax Labs, Inc. (GOVX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, giving investors a structured view of its capital markets activity, governance decisions, and development funding. As a smaller reporting company, GeoVax files registration statements, current reports, and proxy materials that outline its financing transactions, stockholder approvals, and contractual arrangements.
Through registration statements on Form S-1 and Form S-3, GeoVax registers offerings of common stock and warrants, as well as the resale of warrant shares issued in private placements. These filings describe offerings such as registered direct financings and concurrent private placements of common warrants, the number of shares and warrants involved, and intended uses of proceeds, including research and development, manufacturing, clinical studies, capital expenditures, and working capital.
Form 8-K current reports provide details on material events, including the pricing and closing of offerings, entry into placement agency and purchase agreements, government contract developments, and the release of quarterly financial results. 8-K filings also cover special stockholder meetings and the outcomes of votes on proposals such as warrant share issuance approvals and reverse stock split authorizations.
Proxy materials, such as the DEF 14A special meeting proxy statement, outline proposals submitted to stockholders, the rationale for actions like reverse stock splits or warrant exercise approvals, and the mechanics of voting. In addition, Form 25 filings document the removal from listing and/or registration of specific GeoVax securities, such as warrants, from Nasdaq Stock Market LLC.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex documents in plain language. Investors can quickly see the key terms of financing agreements, understand the implications of stockholder votes, and track how government contracts like the BARDA/Project NextGen award are reflected in the company’s disclosures. Real-time updates from EDGAR ensure that new 8-Ks, S-1s, proxy statements, and other filings are available promptly, while dedicated sections for warrant-related disclosures and capital structure changes help users follow the evolution of GOVX’s securities over time.
GeoVax Labs, Inc. received an updated ownership report showing that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together reported beneficial ownership of 4,806,174 shares of common stock as of December 31, 2025. These shares are all issuable upon exercise of three warrants held by Intracoastal and currently represent about 9.99% of the common stock.
The percentage is based on 43,303,682 shares outstanding as of December 22, 2025 plus the warrant shares counted for this calculation. Additional warrant shares are contractually blocked from exercise above ownership caps of 9.99% and 4.99%. The reporting holders certify the position is not held to change or influence control of GeoVax.
GeoVax Labs, Inc. received a Schedule 13G reporting that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, and Waqas Khatri each beneficially own 4,810,451 shares of common stock, or 9.99% of the class as of December 31, 2025.
The reported position consists of 4,810,451 shares of common stock issuable upon exercise of warrants held by the reporting persons, which are subject to 4.99% and 9.99% beneficial ownership blockers. The percentage is based on 43,303,682 GeoVax common shares outstanding as of December 22, 2025.
The reporting persons certify the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of GeoVax Labs, Inc.
GeoVax Labs, Inc. files a prospectus supplement that currently permits additional at-the-market sales of its common stock of up to approximately $3,116,227 through A.G.P./Alliance Global Partners under an existing Form S-3 program. This updates an earlier $30,000,000 at-the-market facility under which the company has already sold 4,525,449 shares for $9,269,560.
The supplement reflects limits under General Instruction I.B.6 of Form S-3, tied to GeoVax’s public float. The aggregate market value of common stock held by non-affiliates is stated as $17,804,611, based on 1,728,603 non-affiliate shares at $10.30 per share as of December 8, 2025, and the company notes it has raised $2,818,643 under this instruction in the past twelve months. GeoVax’s stock trades on the Nasdaq Capital Market under the symbol GOVX, with a last reported price of $3.15 on January 23, 2026.
GeoVax Labs, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock effective upon filing a Certificate of Amendment on January 9, 2026. Every twenty-five shares of existing common stock were automatically combined into one share of new common stock, with the par value per share remaining $0.001.
No fractional shares were issued; any fractional amounts were rounded up to the next whole share. The company states that each stockholder’s percentage ownership and proportional voting power remain essentially the same apart from minor changes from rounding, and the rights and privileges attached to the common stock are substantially unaffected.
GeoVax Labs, Inc. is offering 18,292,683 Common Units and 18,292,683 Pre-Funded Units, plus up to 36,585,366 shares of common stock underlying warrants, in a best efforts public sale. Each Common Unit includes one share of common stock and two five-year Common Warrants exercisable at
Before this deal, GeoVax had 30,058,786 shares outstanding as of December 12, 2025; this would rise to 48,351,469 shares if all Common Units are sold and no warrants are exercised. The company is a clinical-stage biotech with programs including Phase 2 trials for its COVID-19 vaccine candidate GEO-CM04S1, a planned Phase 2 study of its oncolytic therapy Gedeptin for head and neck cancer, and a GEO-MVA Mpox/smallpox vaccine expected to move directly into Phase 3 in 2026.
GeoVax reports it has never generated product revenue, incurred a net loss of approximately
GeoVax Labs, Inc. (GOVX) reported the results of a special stockholder meeting held on November 26, 2025. Stockholders representing 14,125,083 of the company’s 29,705,360 issued and outstanding common shares as of September 30, 2025, were present by proxy.
Stockholders approved a proposal, required under Nasdaq listing rules, to allow the issuance of up to 11,904,768 shares of common stock upon exercise of common stock purchase warrants that were issued to certain institutional investors in a September 30, 2025 private placement. The proposal received 5,806,374 votes for, 946,094 against, and 870,973 abstentions, with 6,501,642 broker non-votes.
They also approved an amendment to the Certificate of Incorporation to implement a reverse stock split of the issued and outstanding common stock at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be set by the Board of Directors. This proposal received 11,850,760 votes for, 2,158,471 against, and 115,852 abstentions.
GeoVax Labs, Inc. filed a current report to note that it released a press release covering its operating results for the quarter ended September 30, 2025. The company states that this press release, dated November 13, 2025, is furnished as Exhibit 99.1 to the report.
The filing also includes standard forward-looking statement language, explaining that projections and expectations are subject to risks and uncertainties, and that actual results may differ from current views. The report is signed on behalf of GeoVax Labs by its Chief Financial Officer, Mark W. Reynolds.
GeoVax Labs, Inc. is supplementing a prospectus covering the resale of up to 1,605,688 shares of common stock by a selling stockholder, incorporating its latest Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
The company reported no revenue in the third quarter from its government contract after BARDA, through the ATI‑RRPV arrangement, terminated that contract for convenience. Third‑quarter 2025 results show a net loss of $6.3 million, bringing the nine‑month net loss to $17.0 million, similar to the prior year despite lower research and development spending.
GeoVax ended the period with $5.0 million in cash and cash equivalents and 29,705,360 shares outstanding, funded largely by multiple equity offerings and warrant exercises that provided about $16.0 million in net financing cash year‑to‑date. Management states that existing cash is expected to fund operations into December 2025 and that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
GeoVax Labs filed a prospectus supplement covering the resale of up to 2,170,000 shares of common stock by a selling stockholder, updating the prospectus with its Form 10‑Q for the quarter ended September 30, 2025.
In the quarter, the company reported a net loss of
FAQ
What is the current stock price of Geovax Labs (GOVX)?
What is the market cap of Geovax Labs (GOVX)?
